Kosh A. Agarwal

Kosh A. Agarwal

Denmark Hill
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 199 publications

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

Journal: The New England journal of medicine

Published: May 28, 2026

What is the emerging role of RNA interference in HBV cure strategies?

What is the emerging role of RNA interference in HBV cure strategies?

Journal: Expert opinion on pharmacotherapy

Published: May 19, 2026

Characterising Hepatitis D Virus in the UK From 2011 to 2021.

Characterising Hepatitis D Virus in the UK From 2011 to 2021.

Journal: Journal of viral hepatitis

Published: March 20, 2026

Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV/HDV co-infection.

Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV/HDV co-infection.

Journal: JHEP reports : innovation in hepatology

Published: March 11, 2026

The UK experience with hepatitis B immunoglobulin use following liver transplantation: wide variation in practice despite evidence supporting cost-effective HBIG-free prophylaxis.

The UK experience with hepatitis B immunoglobulin use following liver transplantation: wide variation in practice despite evidence supporting cost-effective HBIG-free prophylaxis.

Journal: Gut

Published: December 23, 2025

ALG-020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug-Induced Liver Injury.

ALG-020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug-Induced Liver Injury.

Journal: Journal of viral hepatitis

Published: December 12, 2025

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.

Journal: The New England journal of medicine

Published: November 10, 2025

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

Journal: Journal of hepatology

Published: November 05, 2025

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.

Journal: Journal of hepatology

Published: November 05, 2025

No Impact of Low-Dose Nivolumab Addition to JNJ-73763989 on Hepatitis B Surface Antigen Declines in Chronic Hepatitis B: The OCTOPUS-1 Study.

No Impact of Low-Dose Nivolumab Addition to JNJ-73763989 on Hepatitis B Surface Antigen Declines in Chronic Hepatitis B: The OCTOPUS-1 Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 28, 2025

Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis B.

Safety, Tolerability, and Pharmacodynamics of GS-4224 in Healthy Participants and Participants With Chronic Hepatitis B.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 17, 2025

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia.

Course and clinical outcomes of chronic hepatitis delta: a longitudinal analysis of 565 patients from the D-SOLVE and HDV-1000 consortia.

Journal: Gut

Published: July 04, 2025

Showing 1-12 of 199

Last Updated: 09/26/2026